Changes in human epidermal growth factor receptor 2 status between primary breast/gastric carcinomas and synchronous metastatic lymph nodes: how can we explain them?

Abstract

Aim: Previous studies demonstrated discordant expression of human epidermal growth-factor receptor 2 (HER2) between primary cancer and their recurrence/metastasis. This study further evaluated HER2 status between primary gastric and breast invasive carcinomas and paired metastatic disease to lymph nodes.

Methods: This study collected formalin-fixed paraffin-embedded representative tissue blocks from 62 gastric and 65 breast primary carcinomas as well as synchronous metastatic lymph nodes (male:female = 39:88; age ranged between 44 and 95 years with mean age of 69.32 years) for immunohistochemical staining of HER2 expression (DAKO HercepTest™ kit). If immunohistochemical HER2 score reached to 2+, HER2 amplification was then assessed using fluorescence in situ hybridization (PharmDx™ kit DAKO).

Results: The discordant HER2 pooled rate, regardless either negative or positive conversion, was 9.67% in primary gastric carcinoma and corresponding nodal metastasis, while the changes in HER2 expression were revealed in 4.61% of mammary and lymph node neoplastic samples. A high-level concordance in HER2 expression between primary carcinoma and synchronous metastatic lymph nodes was confirmed in both types of cancer; the observed event of discordant HER2 status should be ascribed to intra-tumor heterogeneity, mostly appreciable in gastric cancer.

Conclusion: In any case, the shift from positive to negative HER2 expression suggests that trastuzumab could be the targeted treatment choice whereas the opposite shift should be evaluated by a simultaneous HER2 determination in both primary and metastatic lymph nodes.

Keywords

Breast cancer / epidermal growth-factor receptor 2 / gastric cancer / lymph node / metastasis

References

[1] Ieni A,Caltabiano R,Del Sordo R,Zeppa P,Sidoni A,Tuccari G.Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation..Onco Targets Ther2014;7:1267-72

[2] Ieni A,Giuffrè G,Cascone A,Cabibi D,Lanzafame S,Franco V.Letter to the Editor regarding the paper by Aurilio et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases..Eur J Cancer2014;50:1035-7

[3] Aitken SJ,Langdon SP,Faratian D.Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases..Ann Oncol2010;21:1254-61

[4] Chan A,Brown B,Willsher P.A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease..BMC Cancer2012;12:555 PMCID:PMC3517741

[5] Hoefnagel LD,Meijer SL,Wesseling P,Westenend PJ,Seldenrijk CA,Oudejans J,van Gils CH,van Diest PJ.Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases..Cancer2012;118:4929-35

[6] Aurilio G,Pruneri G,Viale G,Adamoli L,Sciandivasci A,Goldhirsch A.A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases..Eur J Cancer2014;50:277-89

[7] Curtit E,Mansi L,Cals L,Bazan F,Meneveau N,Algros MP.Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis..Oncologist2013;18:667-74 PMCID:PMC4063392

[8] Penault-Llorca F,Hanna WM,Rüschoff J.Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status..Breast2013;22:200-2

[9] Regitnig P,Lindbauer M,Lax SF.Change of HER-2/neu status in a subset of distant metastases from breast carcinomas..J Pathol2004;203:918-26

[10] Santinelli A,Stramazzotti D.HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy..Int J Cancer2008;122:999-1004

[11] Lindström LS,Wilking UM,Hartman J,Hatschek T,Bergh J.Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression..J Clin Oncol2012;30:2601-8

[12] Houssami N,Balleine RL,Pegram MD.HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis..Breast Cancer Res Treat2011;129:659-74

[13] Cardoso F,Fallowfield L,Senkus E.ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2012;23 Suppl 7:vii11-9

[14] Pérez-Fidalgo JA,Ferrer J,Burgués O,Bermejo B,González-Angulo AM.An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer..Breast2013;22:974-9

[15] Turner NH.HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact..Cancer Treat Rev2013;39:947-57

[16] Idirisinghe PK,Cheok PY,Lui PC,Wong NS.Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance..Am J Clin Pathol2010;133:416-29

[17] Kim JH,Lee HS.Comparative analysis of protein expressions in primary and metastatic gastric carcinomas..Hum Pathol2009;40:314-22

[18] Rüschoff J,Baretton G,Walch A,Chenard MP,Nagelmeier I,Höfler H.HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing..Virchows Arch2010;457:299-307 PMCID:PMC2933810

[19] Kim MA,Yang HK,Kim WH.Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma..Histopathology2011;59:822-31 PMCID:PMC3267049

[20] Rüschoff J,Bilous M,Osamura RY,van de Vijver M.HER2 testing in gastric cancer: a practical approach..Mod Pathol2012;25:637-50

[21] Giuffrè G,Barresi V,Tuccari G.HER2 status in unusual histological variants of gastric adenocarcinomas..J Clin Pathol2012;65:237-41

[22] Barresi V,Caruso RA.HER2 status in rarer histologic types of gastric adenocarcinomas..Arch Pathol Lab Med2013;137:741

[23] Bozzetti C,Lagrasta CA,Bassano C,Gardini G,Leonardi F,Camisa R,Silini EM.Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma..Br J Cancer2011;104:1372-6 PMCID:PMC3101935

[24] Kochi M,Masuda S,Mihara Y,Tamegai H,Suda H.Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes..Diagn Pathol2013;8:191 PMCID:PMC3937244

[25] Marx AH,Muth J,Simon R,Kaifi JT,Brümmendorf TH,Izbicki JR.HER-2 amplification is highly homogenous in gastric cancer..Hum Pathol2009;40:769-77

[26] Hofmann M,Shi D,van de Vijver M,Ochiai A,Henkel T.Assessment of a HER2 scoring system for gastric cancer: results from a validation study..Histopathology2008;52:797-805

[27] Ataseven B,Gunesch A,Hoegel B,Eiermann W.HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics..Breast Care (Basel)2012;7:465-70 PMCID:PMC3971811

[28] Falck AK,Chebil G,Fernö M.Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up..Breast Cancer Res Treat2013;140:93-104

[29] Ieni A,Caltabiano R,Bonetti LR,Zeppa P,Tuccari G.Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis..Int J Mol Sci2014;15:22331-41 PMCID:PMC4284711